Applied Genetic Technologies Corp (NASDAQ:AGTC) had its Outperform rating reiterated by Wells Fargo & Co with a $15.00 price target

ME Staff
-
0

Analyst Ratings For Applied Genetic Technologies Corp (NASDAQ:AGTC)

Today, Wells Fargo & Co reiterated its Outperform rating on Applied Genetic Technologies Corp (NASDAQ:AGTC) with a price target of $15.00.

There are 3 Hold Ratings, 3 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Applied Genetic Technologies Corp (NASDAQ:AGTC) is Buy with a consensus target price of $8.6875 per share, a potential 32.43% upside.

Some recent analyst ratings include

  • 12/13/2018-Applied Genetic Technologies Corp (NASDAQ:AGTC) had its Outperform rating reiterated by Wells Fargo & Co with a $15.00 price target
  • 12/13/2018-Applied Genetic Technologies Corp (NASDAQ:AGTC) gets downgraded to Hold by BMO Capital Markets
  • 9/11/2018-Applied Genetic Technologies Corp (NASDAQ:AGTC) gets downgraded to Neutral by Chardan Capital with a price target of $5.00
  • 2/9/2018-Applied Genetic Technologies Corp (NASDAQ:AGTC) had its Outperform rating reiterated by Wedbush
  • 1/17/2018-Applied Genetic Technologies Corp (NASDAQ:AGTC) had its Hold rating reiterated by Cantor Fitzgerald with a $9.00 price target


  • On 11/16/2016 Ivana Magovcevic, Director, bought 3,000 with an average share price of $9.63 per share and the total transaction amounting to $28,890.00.
  • On 11/1/2016 Jeffrey D Chulay, VP, sold 1,000 with an average share price of $7.05 per share and the total transaction amounting to $7,050.00.
  • On 9/22/2016 Mark S Shearman, Insider, bought 3,000 with an average share price of $8.87 per share and the total transaction amounting to $26,610.00.
  • On 9/20/2016 Stephen W Potter, Insider, bought 1,400 with an average share price of $8.89 per share and the total transaction amounting to $12,446.00.
  • On 9/19/2016 Lawrence E Bullock, CFO, bought 10,000 with an average share price of $8.75 per share and the total transaction amounting to $87,500.00.
  • On 2/23/2015 Plc Glaxosmithkline, Major Shareholder, sold 503,150 with an average share price of $22.00 per share and the total transaction amounting to $11,069,300.00.
  • On 1/23/2015 Daniel L Menichella, VP, sold 1,996 with an average share price of $24.90 per share and the total transaction amounting to $49,700.40.

About Applied Genetic Technologies Corp (NASDAQ:AGTC)
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology. It has collaboration agreements with Biogen MA, Inc., Synpromics Limited, and Bionic Sight, LLC, as well as the University of Florida Research Foundation. The company was founded in 1999 and is headquartered in Alachua, Florida.

Recent Trading Activity for Applied Genetic Technologies Corp (NASDAQ:AGTC)
Shares of Applied Genetic Technologies Corp closed the previous trading session at 6,56 +0,45 7,36 % with 341700 shares trading hands.